|
|
 |
ASPARTAME Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ALBUMIN HUMAN Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
AMMONIO METHACRYLATE COPOLYMER TYPE B Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
BENZALKONIUM CHLORIDE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ALPHA-TOCOPHEROL Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ALCOHOL Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
AMMONIA Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
AMMONIUM GLYCYRRHIZATE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ACESULFAME POTASSIUM Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|